The FDA action won’t have an immediate impact on sales of Ocaliva because the majority of patients taking the drug don’t have advanced cirrhosis, according to Intercept. The company prepared investors for the move earlier this month when it released first-quarter financial results.
Still, the additional warning to doctors may affect future prescriptions, SVB Leerink analyst Thomas J. Smith wrote in a note to investors.
